Posters

Bone development

P1 How to grow a synovial joint: the cell-level activities underlying prenatal joint morphogenesis
Niamh Nowlan (Dublin, Ireland)

P2 Observational study of fetal foramen magnum and foramen magnum stenosis development in Achondroplasia
Rhoda Akilapa (London, UK)

P3 Variation in skeletal robustness is an important determinant of bone strength in youth and young adults in both males and females
Vanessa Yingling (Hayward, USA)

P4 ABSTRACT WITHDRAWN

P5 Variations of the trabecular bone microarchitecture through the period of locomotor behaviour development of a late 19th century post-industrial Italian population.
Antony Colombo (Pessac cedex, France)

P6 Comparison of cortical bone outcomes in the metaphysis and diaphysis during growth
Kyla Kent (Palo Alto, USA)

P7 The applicability and agreement between two methods of bone age assessment in Zimbabwean children and adolescents
Farirayi Kowo-Nyakoko (Harare, Zimbabwe)

P8 Predictors of skeletal maturity in Zimbabwean children and adolescents
Farirayi Kowo-Nyakoko (Harare, Zimbabwe)

P9 Fun with 50: testing the legend of height prediction at age two
Dana Duren (Columbia, USA)

POSTER KEY

P1-P9	Bone development
P10-P25	Bone fragility
P26-P36	Bone metabolism
P37-P49	Diagnostics and imaging
P50-P55	Genetics
P56-P77	Medical therapies
P78-P87	Mineral homeostasis and vitamin D
P88-P96	Muscle and bone
P97-P101	Nutrition
P102-P103	Orthopaedics
P104-P114	Other
P115-P173	Rare bone diseases
LM4-LM29	Last minute abstracts
Unnumbered	Challenge the Expert cases

Bone fragility

P10 Elevated bone turnover markers predict increased bone mineral density in adolescents with congenital adrenal hyperplasia
Pattara Wiromrat (Khon Kaen, Thailand)

P11 Bone health in patients with type 1 diabetes and progressive eGFR decline from adolescence into young adulthood
Funmbi Babalola (Toronto, Canada)

P12 Does body mass index influence the risk of vertebral fractures in children with osteogenesis imperfecta?
Sameera Auckburally (Manchester, UK)

P13 Spontaneous reshaping of vertebral fractures in primary and secondary osteoporosis
Rodrigo Montero-Lopez (Linz, Austria)

P14 Pubertal growth in osteogenesis imperfecta caused by pathogenic variants in COL1A1/COL1A2
Marie-Eve Robinson (Ottawa, Canada)

P15 Burden of steroid use in the treatment of Duchenne Muscular Dystrophy: Findings from a targeted literature review, online survey and qualitative research as part of Project HERCULES
Caleb Hariri (Shotts, UK)

P16 Histomorphometric answers to vertebral changes in sickle cell disease.
Sophia Sakka (London, UK)

P17 Platelet-derived growth factor type BB is decreased in boys with Duchenne Muscular Dystrophy on chronic glucocorticoids without history of fracture
Julia See (Miami, USA)

P18 SMAD3 mutation in LDS3 causes bone fragility by impairing the TGF-β pathway and enhancing osteoclastogenesis
Ahmed El-Gazzar (Linz, Austria)

P19 Risk of chronic diseases among children with a significant fracture history
Yael Levy Shraga (Ramat Gan, Israel)

P20 Use of zoledronate in children with sickle cell disease: a single centre experience
Sophia Sakka (London, UK)

P21 Use of oral risedronate in children with osteoporosis during Covid pandemic: Evelina experience
Jaya Sujatha Gopal-Kothandapani (London, UK)

P22 Horizonal gaze palsy with progressive scoliosis secondary to ROBO3 gene variants associated with osteogenesis imperfecta type I
Belinda Crowe (London, UK)

Posters

P23 Catastrophic vertebral fracture cascade in boys with Duchenne muscular dystrophy on long-term glucocorticoids
Nicola Crabtree (Birmingham, UK)

P24 KDELR2-related osteogenesis Imperfecta (OI21): clinical and radiological features in two siblings with novel compound heterozygous intragenic deletions
Catherine DeVile (London, UK)

P25 Multiple vertebral fractures: Was the cause hiding in plain sight: Lifestyle?
Toby Candler (Bristol, UK)

Bone metabolism

P26 Hereditary hypophosphatemic rickets and osteomalacia - an uncommon cause of metabolic bone disease
Shivani Shivani (Bathinda, India)

P27 The results of pharmaceutical therapy for structural disorders of bone in patients with fibrous dysplasia
Alexander Skuratov (Kyiv, Ukraine)

P28 Novel PTH gene mutations causing isolated hypoparathyroidism
Michael Levine (Philadelphia, USA)

P29 The peculiarity of the bone metabolism in children with Wilson's disease
Nataliya Balatska (Kyiv, Ukraine)

P30 Skeletal remodelling and resolution of recurrent severe hypercalcaemia following withdrawal of prolonged denosumab after haematopoietic stem cell transplant for TNFRSF11A osteopetrosis
Christine Burren (Bristol, UK)

P31 Osteocalcin drives metabolic adaptation in a mouse model of severe dominant Osteogenesis Imperfecta.
Josephine Tauer (Montreal, Canada)

P32 Coeliac disease presenting with vertebral fractures in a child with multiple epiphyseal dysplasia
Stephanie Borg (Sheffield, UK)

P33 Adiponectin has a pro-resorption role on bone in childhood-onset brain tumors
Natascia di Iorgi (Genoa, Italy)

P34 Spontaneous remission of hypophosphataemic rickets in a child.
Nick Shaw (Birmingham, UK)

P35 Transient hyperphosphatasemia in a child with autism spectrum disorder
Stepan Kutilek (Klatovy, Czech Republic)

P36 Serum osteocalcin levels in children with steroid-resistant nephrotic syndrome
Aashima Dabas (New Delhi, India)

Diagnostics and imaging

P37 Reduced responsivity of the skull to stimuli associated with bone mineralisation at other skeletal sites in children
Rebecca Moon (Southampton, UK)

P38 Radiology reporting of paediatric osteoporotic vertebral fractures in Duchenne muscular dystrophy and potential impact on clinical management
Hannah Martin (Glasgow, Scotland)

P39 An unusual case of transient cardiac calcification identified on antenatal echocardiography – A Generalised Arterial Calcification of Infancy (GACI) like presentation.
Jananie Suntharesan (Liverpool, UK)

P40 Selective venous sampling solves the localisation dilemma in primary hyperparathyroidism.
Nandhini Perumal (Manchester, UK)

P41 Parametric analysis of a method to non-invasively quantify bone remodeling using time-lapse high-resolution peripheral quantitative computed tomography imaging from individuals with OI
Seyedmahdi Hosseinitabatabaei (Montreal, Canada)

P42 Cortical bone mass by the BoneXpert method in children and adolescents with Klinefelter syndrome.
Jean De Schepper (Brussels, Belgium)

P43 What's in a name? Prevalence of metaphyseal fractures in children with osteogenesis imperfecta in the first two years of life
Ella Riley (Sheffield, England)

P44 Osteoporosis diagnosis in adolescents by means Radiofrequency Echographic Multi Spectrometry (REMS)
Carla Caffarelli (Siena, Italy)

P45 Evidence for metaphyseal fractures typical of abuse in osteogenesis imperfecta: A Systematic Review
Ella Riley (Sheffield, England)

P46 Post-operative X-rays in pediatric supracondylar fractures: what is their role?
Ammar Abusultan (Al Khobar, Saudi Arabia)

P47 MRI investigation of vertebral changes in children with sickle cell disease
Jaya Sujatha Gopal-Kothandapani (London, UK)

P48 Joint effusions as a radiographic feature of complex chronic recurrent multifocal osteomyelitis (CRMO)
Ioanna Tsigkouli (Stanmore, UK)

P49 A reference range for plasma levels of inorganic pyrophosphate in children
Eva Bernhard (Münster, Germany)

Genetics

P50 Dominant osteogenesis imperfecta caused by a heterozygous SP7 variant
Karissa Ludwig (Montreal, Canada)

P51 Interrogating causal effects of epidemiological risk factors on adolescent idiopathic scoliosis (AIS): a two-sample Mendelian randomization study
Faegheh Ghanbari (Montreal, Canada)

P52 Inherited bone marrow failure syndromes: retrospective review of NGS panel testing in affected individuals
Thomas Borge (Espoo, Finland)

P53 Eiken dysplasia with parathyroid hormone resistance: two new paediatric cases with the same novel variant.
Alistair Calder (London, UK)

P54 Severe osteoporosis in an adolescent male with PTEN hamartoma tumour syndrome (PHTS).
Sapna Nayak (Manchester, UK)

P55 A de novo deleterious PHEX variant with no evidence of X-linked hypophosphatemia
Michelle Kayser (New Haven, CT, USA)

Medical therapies

P56 Combination of amiloride and hydrochlorothiazide improved mineral metabolism while effectively lowering urinary calcium excretion in a patient with autosomal dominant hypocalcemia type 1 due to a novel gain-of-function mutation in the calcium-sensing receptor gene
Matthew Benson (Jacksonville, USA)

P57 Hypogonadism and low bone mineral density in adolescent males with cerebral palsy
Alicia Diaz-Thomas (Memphis, USA)

P58 Stepwise approach to loop diuretic-induced secondary hyperparathyroidism in children
Darcy Weidemann (Kansas City, USA)

P59 Radiological and histomorphometric characteristic of two peripubertal X-Linked Hypophosphatemic children treated with burosumab till the end of growth
Raja Padidela (Manchester, UK)

P60 Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone
Diana-Alexandra Ertl (Vienna, Austria)

P61 Outcome of intravenous bisphosphonate greater than two years in Duchenne muscular dystrophy: A preliminary report
Hannah Martin (Glasgow, Scotland)

P62 An appraisal of a spine screening programme for vertebral fracture and its management in Duchenne Muscular Dystrophy:Is it time to reconsider threshold for treatment with bisphosphonate?
Hannah Martin (Glasgow, Scotland)

P63 Meniere's syndrome secondary to X-linked hypophosphatemic rickets (XLHR) in an adolescent - Successfully managed with Burosumab treatment.
Jananie Suntharesan (Liverpool, UK)

P64 Dental health of pediatric patients with X-linked hypophosphatemia under one year of burosumab therapy
Avivit Brener (Tel Aviv, Israel)

P65 Resolution of tumoral calcinosis lesion and hyperostosis by Acetazolamide in hyperphosphatemic familial tumoral calcinosis and hyperostosis syndrome
Pon Ramya Gokul (Manchester, UK)

P66 Severity of acute phase reaction in children receiving first dose of zoledronic acid – impact of the underlying condition
Sapna Nayak (Manchester, UK)

P67 Lipohypertrophy results in worsening of the disease state in a patient with perinatal onset hypophosphatasia treated with subcutaneous Asfotase alfa.
Lauren Rayner (Manchester, England)

P68 Boost brittle bones before birth: a clinical trial on stem cell transplantation for treatment of osteogenesis imperfecta
Cecilia Götherström (Stockholm, Sweden)

P69 Six-month safety and efficacy of asfotase alfa in a child with phosphatidylinositol glycan anchor biosynthesis class N mutation
Janet Crane (Baltimore, USA)

P70 Two years safety and efficacy outcomes of burosumab in cutaneous skeletal hypophosphatemia syndrome (CSHS)
Rachel Gafni (Bethesda, USA)

P71 ABSTRACT WITHDRAWN

P72 Early experience of treatment of aneurysmal bone cyst with a combination of zoledronic acid and denosumab
Benjamin Jacobs (Stanmore, UK)

P73 Growth hormone and/or testosterone prolong time to next vertebral compression fracture in dystrophinopathies managed with chronic glucocorticoids
Emely Loscalzo (Baltimore, US)

P74 Hypophosphataemic rickets secondary to McCune- Albright syndrome: successful treatment with burosumab.
Jeremy Allgrove (London, UK)

P75 Use of anti-FGF23 monoclonal antibody in the treatment of children and adolescents with X-linked hypophosphatemic rickets: argentine experience.
Hamilton Cassinelli (CABA, Argentina)

P76 A retrospective study of the biochemical and radiological profile of children with genetic hypophosphatemic rickets and their response to conventional therapy
Kebashni Thandrayen (Johannesburg, South Africa)

P77 Complications of high dose Denosumab as adjuvant therapy for recurrent pediatric giant cell tumor of the maxilla
Vivian Szymczuk (Bethesda, USA)

Mineral homeostasis and vitamin D

P78 Vitamin D supplementation during pregnancy increases offspring birth weight and calcium status: a meta-analysis of intervention studies
Rebecca Moon (Southampton, UK)

P79 25-hydroxyvitamin D testing in paediatric secondary care: an audit of current practice
Rebecca Moon (Southampton, UK)

P80 Collagen X biomarker, early childhood linear growth and bone development in a Vitamin D intervention study in Infants
Helena Hauta-alus (Helsinki, Finland)

P81 Developmental loss of calcium-sensing receptor compensatory response to inflammation in burns
Gordon Klein (Galveston, USA)

P82 ABSTRACT WITHDRAWN

P83 Daily versus weekly oral vitamin D3 therapy for nutritional rickets in Indian children: A randomized controlled open-label trial
Aashima Dabas (New Delhi, India)

P84 Systematic review of vitamin D supplementation in Duchenne muscular dystrophy
Jarod Wong (Glasgow, UK)

P85 Barakat syndrome -description of two cases
Stepan Kutilek (Klatovy, Czech Republic)

P86 Clinical course of hypoparathyroidism in children with autoimmune polyendocrine syndrome type-1
Saila Laakso (Helsinki, Finland)

P87 ABSTRACT WITHDRAWN

Muscle and bone

P88 Anti-RANKL therapy prevents glucocorticoid induced bone loss and promotes muscle function in a mouse model of Duchenne muscular dystrophy
Soher Jayash (Edinburgh, UK)

P89 A multi-disciplinary approach for bone-endocrine care in Duchenne Muscular Dystrophy: The Glasgow experience
Jarod Wong (Glasgow, UK)

P90 A national survey of bone-endocrine monitoring in boys with Duchenne muscular dystrophy and the patients' experience to inform a UK wide project to implement standards of care (DMD Care UK)
Jarod Wong (Glasgow, UK)

P91 Physical impairments and activity limitations of childhood acute lymphoblastic leukemia survivors: A PETALE cohort study
Annie Brochu (Montreal, Canada)

P92 Delayed puberty is very common in boys with Duchenne muscular dystrophy on daily glucocorticoid
Jarod Wong (Glasgow, UK)

P93 Children with neurofibromatosis type 1 have significant deficits in muscle function
Amish Chinoy (Manchester, UK)

P94 Whole-body vibration training in addition to muscle-strengthening exercises alone in improving muscle function in children with neurofibromatosis type 1 – a randomised interventional trial
Amish Chinoy (Manchester, UK)

P95 Transgender youth on gonadotropin agonist have lower BMD scores but muscle strength remained similar to controls
Tandy Aye (Palo Alto, USA)

P96 Development of musculoskeletal deficits in children with cystic fibrosis in later childhood
Alex Ireland (Manchester, UK)

Nutrition

P97 Comparison of infant and maternal vitamin D supplementation perspectives and practices: a cross-sectional survey study
Andrea Aul (Rochester, USA)

P98 ABSTRACT WITHDRAWN

P99 Changes in biomarkers of bone turnover and incretin hormones following glucose ingestion in adolescents and young adults with pancreatic insufficient cystic fibrosis
Wang Shin Lei (Athens, USA)

P100 An audit examining the vitamin D status, prophylaxis, and treatment of vitamin D deficiency for patients in the Spinal and Scoliosis Service at Children's Health Ireland Temple Street
Ciara McDonnell (Dublin, Ireland)

P101 ABSTRACT WITHDRAWN

Orthopaedics

P102 Radiological wrist abnormalities in patients with transfusion-dependent beta-thalassemia major
Vineet Dabas (New Delhi, India)

P103 Surgical timing and surgeon level in supracondylar humerus fractures in pediatric patients: is there an effect on prognosis?
Jaffar Alsayigh (Al Khobar, Saudi Arabia)

Other

P104 Singleton-Merten-Syndrome – from diagnosis to targeted therapy
Katrin Heldt (St Gallen, Switzerland)

P105 ABSTRACT WITHDRAWN

P106 Adolescents with premature ovarian insufficiency show impaired trabecular and cortical bone density compared to normally menstruating age and BMI matched controls
Halley Wasserman (Cincinnati, USA)

P107 Prevalence of low bone density in patients with epidermolysis bullosa: insight from a large single center's experience
Halley Wasserman (Cincinnati, USA)

P108 Descriptive study of screening and management of metabolic bone disease of prematurity in Neonatal Intensive-Care Unit at Montreal Children's Hospital
Anne Marie Sbrocchi (Montreal, Quebec)

P109 GEnomics of MusculoSkeletal traits TranslatiOnal NEtwork (GEMSTONE): Research focused on Real-World needs
Inês Alves (Évora, Portugal)

P110 Insights into the launch of an international network for new investigators in the field of pediatric bone health
Adalbert Raimann (Vienna, Austria)

P111 Development of a Dental Care Pathway for children attending a Rare Bone Disorder service at a tertiary hospital.
Eleanor Mc Govern (Dublin, Ireland)

P112 Evaluation of quality, time, and cost-effectiveness of the virtual platform in multi-agency management of osteogenesis imperfecta during COVID-19 pandemic.
Nicola Panchbhaya (Manchester, UK)

P113 New standards for craniofacial growth
Richard Sherwood (Columbia, USA)

P114 A dual centre transition clinic for young people with mild, moderate and severe osteogenesis imperfecta
Mark Heathfield (London, UK)

Rare bone diseases

P115 Palovarotene for the treatment of fibrodysplasia ossificans progressiva: methodology of the Phase III Open-Label PIVOINE Rollover Trial
Alexander Artyomenko (Slough, UK)

P116 IPN60130 for the treatment of fibrodysplasia ossificans progressiva: methodology of the Randomized, Double-Blind, Placebo-Controlled Phase II FALKON Trial
Fei Shih (Cambridge, USA)

P117 First interim analysis of the international X-linked hypophosphataemia registry: paediatric baseline auxological characteristics
Zulf Mughal (Manchester, UK)

P118 Lower limb maltorsion in children and adolescents with XLH
Gabriel Mindler (Vienna, Austria)

P119 Persistent lower limb deformities in X-linked hypophosphatemia (XLH) under Burosumab therapy: Preliminary short term results
Gabriel Mindler (Vienna, Austria)

P120 A systematic review of the effectiveness and safety of therapeutic options for patients with achondroplasia and clinical unmet need
Alden Smith (Palo Alto, USA)

P121 A systematic review on the clinical burden of achondroplasia and management of achondroplasia-associated complications
Wahidullah Noori (Palo Alto, USA)

P122 A novel LRRK1 mutation causing osteosclerotic metaphyseal dysplasia (OSMD)
Chariklia Pieridou (Coventry, UK)

P123 Gait deviations and burden of disease in children with XLH
Alexandra Stauffer (Vienna, Austria)

Posters

P124 ABSTRACT WITHDRAWN

P125 Giant cell tumour in lumbar spine of an 11-year-old girl – surgical and medical treatment with zoledronate and denusomab
Signe Beck-Nielsen (Aarhus, Denmark)

P126 Annual hearing screening in children with achondroplasia: results from the first 2 years in Glasgow
Adam Watt (Glasgow, UK)

P127 Weaker bones relative to body size in patients with thalassemia compared to healthy controls
Vanessa Yingling (Hayward, USA)

P128 Foramen magnum stenosis in infants with achondroplasia: investigating the natural history of cervicomedullary cord compression without signal change
Connor Brett (London, UK)

P129 Children with hypophosphatasia treated with asfotase alfa: interim analysis from the UK Cohort
Raja Padidela (Manchester, UK)

P130 Quantifying outcomes in fibrodysplasia ossificans progressiva (fop) by patient age: results from an international burden of illness survey
Kim Croskery (Slough, UK)

P131 Circulating collagen fragments as indicators for growth in children with achondroplasia
Merete Ljungberg (Copenhagen, Denmark)

P132 Reduced bone mineral accrual in pediatric patients with thalassemia
Ellen Fung (Oakland, USA)

P133 Parathyroid adenoma associated with Neurofibromatosis type 1 (NF1) – A rare paediatric presentation.
Jananie Suntharesan (Liverpool, UK)

P134 Two heterozygous sequence variants of the CTSK gene in a girl with very small stature
Milan Bayer (Prague, Czech Republic)

P135 Identification of the CLCN7 mutation in children cause autosomal dominant osteopetrosis type II
Voraluck Phatarakijnirund (Bangkok, Thailand)

P136 Systematic review of muscle mass and muscle function in osteogenesis imperfecta
Caleb Hariri (Shotts, UK)

P137 Co-existence of osteogenesis imperfecta and hypophosphatasia pathological bone features in a 3-year-old boy with multiple bone fractures and mutations in COL1A1 and ALPL.
Nadja Fratzl-Zelman (Vienna, Austria)

P138 Early experience with vosoritide therapy in clinical practice
Valérie Cormier-Daire (Paris, France)

P139 Vosoritide for children with achondroplasia: growth velocity and pubertal milestones
Melita Irving (London, UK)

P140 Associations between height and health-related quality of life (HRQoL) and functional independence in children with achondroplasia
Melita Irving (London, UK)

P141 Should osteogenesis imperfecta be labeled as a low bone mass condition?
Cathleen Raggio (New York, USA)

P142 Skeletal disease acquisition in fibrous dysplasia: natural history and indicators of lesion progression in children
Vivian Szymczuk (Bethesda, Maryland, USA)

P143 Effects of a two-week intensive training program on motor skills and mobility in children and adolescents with musculoskeletal diseases
Sandra Baumann (Linz, Austria)

P144 Using virtual communication for rapid dissemination of COVID-19 information to individuals with osteogenesis imperfecta
Laura Tosi (Washington, DC, USA)

P145 Craniosynostosis in autosomal dominant hypophosphatemic rickets treated with ferrous sulfate
Kelli Davis (Nashville, USA)

P146 ABSTRACT WITHDRAWN

P147 ACHieve Study: baseline characteristics of a multicenter observational study of children with achondroplasia
Melita Irving (London, UK)

P148 Baseline characteristics of the ACcomplisH phase 2 trial evaluating once-weekly TransCon CNP in children with achondroplasia
Ciara McDonnell (Dublin, Ireland)

P149 Serum phosphorus levels as a driver of skeletal morbidity in patients with fibrous dysplasia
Zubeyir Hasan Gun (Bethesda, USA)

P150 Do children aged 7-12 years old with achondroplasia have appropriate adaptations required to support independence in toileting?
Kathryn Johnson (London, UK)

P151 Are children with achondroplasia able to use the toilet independently on entry to primary school?
Paul Watson (London, UK)

P152 Evaluation of multidisciplinary care of children with chronic metabolic bone conditions at Royal Manchester Children's Hospital
Nicola Panchbhaya (Manchester, UK)

Posters

P153 Investigating the effect of a novel ASCC1 deletion mutation on human bone fragility
Barbara Voraberger (Linz, Austria)

P154 Functional testing of variants of uncertain significance in the ALPL gene: First results of the Hypophosphatasia gene variant consortium
Ahmed El-Gazzar (Linz, Austria)

P155 Hyperphosphatemic familial tumoral calcinosis: a case report
Yael Levy Shrag (Ramat Gan, Israel)

P156 Insights into endothelial and stromal microenvironment of osteosarcoma based on two cohorts of patients.
Valérie Trichet (Nantes, France)

P157 The diagnostic odyssey: lessons from Tin Soldiers and the search for undiagnosed individuals with fibrodysplasia ossificans progressiva (FOP)
Christiaan Scott (Cape Town, South Africa)

P158 The European Registries for Rare Bone and Mineral Conditions (EuRR-Bone): focusing on the core registry and disease specific modules
Diana-Alexandra Ertl (Paris, France)

P159 Treatment approach for hypophosphatasia with highly purified human mesenchymal stem cells "REC"
Takeshi Taketani (Izumo-city, Japan)

P160 The global Hypophosphatasia Gene Variant Database: Dedicated to deciphering variants
Mariam Farman (Linz, Austria)

P161 Relapse of giant cell granuloma on denosumab weaning as shown using semi-quantification of technetium Tc 99m hydroxydiphosphonate (Tc99m-HDP) uptake on SPECT imaging.
Poonam Dharmaraj (Liverpool, Merseyside)

P162 Engaging the osteogenesis imperfecta (OI) community in patient centered outcomes research
Laura Tosi (Washington, USA)

P163 Pseudohypoparathyroidism: focus on neonatal features, a retrospective analysis of a large cohort of patients
Giulia Del Sindaco (Milan, Italy)

P164 Annual hearing screening in children with osteogenesis imperfecta: results from first three years in Glasgow
Emmett Lui (Glasgow, Scotland)

P165 Phenotypic and genotype spectrum in a cohort of patients with Osteogenesis Imperfecta.
Nalini M Selveindran (Selangor, Malaysia)

P166 Mechanical regulation of bone healing is altered in mouse models of osteogenesis imperfecta
David Bertrand (Montreal, Canada)

P167 Primary hypertrophic osteoarthropathy: a case report with genetic and rheumatology evaluation and literature review
Marija Mijovic (Belgrade, Serbia)

P168 Hypochondroplasia: why are we still missing its diagnosis?
Anna Allegri (Genova, Italy)

P169 What is the impact of achondroplasia on function in children as measured by the Pediatric Evaluation of Disability Inventory- Computer Adaptive Test (PEDI-CAT)?
Jill Massey (London, UK)

P170 Multiple pathological fractures as a clinical sign of parathyroid adenoma in adolescent: a case report
Frida Soesanti (Jakarta, Indonesia)

P171 Craniofacial lesion progression in patients with fibrous dysplasia
Jocelyn Taylor (Bethesda, USA)

P172 Panostotic fibrous dysplasia in newly diagnosed McCune Albright syndrome: an Indonesia experience
Frida Soesanti (Jakarta, Indonesia)

P173 Insight into the bone dysplasia mechanism of CRTAP-null osteoblasts
Aileen Barnes (Bethesda, USA)

Last minute abstracts

LM4 A severe phenotype of Bruck syndrome caused by biallelic PLOD2 variant with additional phenotypic features of congenital cardiac disease and pulmonary haemorrhage.
Craig Munns (Brisbane, Australia)

LM5 Novel adapation to the SARC-F score to classify pediatric hemato-oncology patients with functional sarcopenia
Emma Verwaaijen (Utrecht, Netherlands)

LM6 Are we undertreating calcium deficiency in metabolic bone disease of prematurity? A case report
Sirisha Kusuma Boddu (Hyderabad, India)

LM7 Phenotyping fibrodysplasia ossificans progressiva using UK primary care electronic health records
Orlando Buendia (London, UK)

LM8 Late-onset severe primary hyperparathyroidism due to a novel homozygous CaSR mutation and the use of pamidronate in the post-operative management
Sirisha Kusuma Boddu (Hyderabad, India)

Posters

LM9 The IMPACT survey provides unique insights into the self-reported experiences of adolescents with osteogenesis imperfecta (OI) through a novel 95-participant dataset
Oliver Semler (Cologne, Germany)

LM10 Van Neck-Odelberg disease and its relevance to the painful hip in children
Daniela Dyankova (London, UK)

LM11 How we made an Impact – The role of Patient Advocacy Groups in recruitment to surveys on rare conditions
Ingunn Westerheim (Oslo, Norway)

LM12 Characterization of pediatric inpatient admissions due to significant hypocalcemia with vitamin D deficiency
Nadia Merchant (Washington, USA)

LM13 Coned epiphyses with severe short stature in patient with abetalipoproteinemia
Rashida Farhad Vasanwala (Singapore, Singapore)

LM14 Establishing the prevalence of osteomalacia in Arab adolescents using nutritional biomarkers of bone health
Nasser Al-Daghri (Riyadh, Saudi Arabia)

LM15 Nontraumatic bilateral femoral and humerus fractures in an adolescent during a hypocalcemic seizure
Sapna Nayak (Lucknow, India)

LM16 Atypical femoral fracture in type 1 osteogenesis imperfecta after discontinuation of bisphosphonate treatment
Rebecca Moon (Southampton, UK)

LM17 Assessment of health status of newborns with severe osteogenesis imperfecta – 21 years of observations
Jakub Nowicki (Lodz, Poland)

LM18 Vitamin D and osteocalcin levels among children with osteogenesis imperfecta – one-year observations
Jakub Nowicki (Lodz, Poland)

LM19 Cross-sectional structure of cortical bone at the femoral midsection during early locomotor progression
Karen Swan (London, UK)

LM20 Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency appears to be associated with an evolving skeletal dysplasia in addition to ectopic calcification and rickets
Deborah Wenkert (Thousand Oaks, USA)

LM21 Ethanolic extract from C8 promotes fracture healing by reducing ROS level
Kriti Sharma (Lucknow, India)

LM22 ABSTRACT WITHDRAWN

LM23 Premature epiphyseal fusion induced by a retinoic acid agonist in a young patient with fibrodysplasia ossificans progressiva
Sigrún Hallgrímsdóttir (Solna, Sweden)

LM24 Influence of chronic inflammation on bone mineral density in children with epidermolysis bullosa
Natalia Balatska (Kyiv, Ukraine)

LM25 Multicentric carpotarsal osteolysis syndrome. A Case Report
Kelly Maury (Buenos Aires, Argentina)

LM26 Metachondromatosis: Description of 5 new patients with a novel variant in PTPN11
Rhoda Akilapa (London, UK)

LM27 Juvenile psammomatoid ossifying fibroma (JPOF) in the radius: A rare cause of tumour induced osteomalacia
Benjamin Jacobs (Stanmore, UK)

LM28 Bruck syndrome - description of the first Polish infant with FKBP10 gene mutation
Jakub Nowicki (Lodz, Poland)

LM29 Vitamin D status and bone mineral density in children with allogeneic hematopoietic cell transplantation due to oncohematology
Natalia Balatska (Kyiv, Ukraine)

Challenge the Expert Cases

A case of neonatal osteofibrous dysplasia with novel CDK12 and DDR2 mutations
Ammar Abusultan (Al Khobar, Saudi Arabia)

Achondroplasia in a three-year-old male
Siska Lubis (Medan, Indonesia)

Cutaneous-skeletal hypophosphatemic syndrome
Margaret Zacharin (Melbourne, Australia)

Tumoral calcinosis
Margaret Zacharin (Melbourne, Australia)

OI/OI-like due to mutation in BMP1
Margaret Zacharin (Melbourne, Australia)